Fresh off of a successful IPO, Avalyn Pharma CEO Lyn Baranowski describes the company's inhaled medicines platform, and shares her secrets to success as a leader

Interviewed by Sisterhood editorial board member Erika Smith, Lyn Baranowski highlights the company's $345 million IPO, which enables it to further develop its inhaled medicines. She describes why they believe this delivery method provides a more direct and efficient way to treat fibrotic lung conditions like IPF.